key: cord-0827470-vfabj0ph
authors: Oba, J.; Taniguchi, H.; Sato, M.; Takanashi, M.; Yokemura, M.; Sato, Y.; Nishihara, H.
title: SARS-CoV-2 RT-qPCR testing of pooled saliva samples: a case study of 824 asymptomatic individuals and a questionnaire survey in Japan
date: 2022-02-02
journal: nan
DOI: 10.1101/2022.02.02.22269880
sha: e42e701e5bad666b077758ac60cb09571331bb82
doc_id: 827470
cord_uid: vfabj0ph

From the beginning of the COVID-19 pandemic, the demand for diagnostic and screening tests has exceeded supply. Although the proportion of vaccinated people has increased in wealthier countries, breakthrough infections have occurred amid the emergence of new variants. Pooled-sample COVID-19 testing using saliva has been proposed as an efficient, inexpensive, and non-invasive method to allow larger-scale testing, especially in a screening setting. In this study, we aimed to evaluate pooled RT-qPCR saliva testing and to compare the results with individual tests. Employees of Philips Japan, Ltd. were recruited to participate in COVID-19 screening from October to December 2020. Asymptomatic individuals (n=824) submitted self-collected saliva samples. Samples were tested for the presence of SARS-CoV-2 by RT-qPCR in both 10-sample pools and individual tests. We also surveyed participants regarding their thoughts and behaviors after the PCR screening project. Two of the 824 individuals were positive by RT-qPCR. In the pooled testing, one of these two had no measurable Ct value, but showed an amplification trend at the end of the PCR cycle. Both positive individuals developed cold-like symptoms, but neither required hospitalization. Of the 824 participants, 471 responded to our online questionnaire. Overall, while respondents agreed that PCR screening should be performed regularly, the majority were willing to undergo PCR testing only when it was provided for free or at low cost. In conclusion, pooled testing of saliva samples can support frequent large-scale screening that is rapid, efficient, and inexpensive.

The COVID-19 pandemic has altered our daily lives. Although vaccination programs have progressed in many countries, daily infections and hospitalizations are still high globally (1, 2) .

Moreover, breakthrough infections in fully vaccinated individuals have been reported, indicating that such people can still contract and transmit the virus (3) (4) (5) . One of the challenges in controlling this disease is that the spread of SARS-CoV-2 infection occurs not only in symptomatic patients but also in asymptomatic carriers, including many who later develop symptoms (presymptomatic cases) (6) (7) (8) .

Further, as community transmission continues, new variants are likely to emerge; when we drafted this manuscript, the highly transmissible Delta variant had replaced the majority of strains worldwide, but started to be replaced by a newer variant Omicron (9) .

Early identification and isolation of infected individuals through comprehensive screening is effective in minimizing the spread of infection. The gold standard diagnostic test for SARS-CoV-2 infection is real-time reverse transcription -polymerase chain reaction (RT-qPCR) using upper respiratory tract specimens (10) . While nasopharyngeal swabs (NPS) have been the most widely used sample type, collecting NPS samples requires trained personnel and personal protective equipment (PPE), increasing infection risks to both patients and healthcare workers; moreover, it causes discomfort and a potential risk of complications to patients because of the anatomical structures of the nasal cavity (11) (12) (13) . These factors have limited the widespread use of NPSs.

Using saliva samples is an attractive alternative. It has advantages over NPS samples: it is much less invasive and allows self-collection, making it more feasible for repeated, frequent testing; it minimizes the infection risk during sample collection; and has lower personnel and PPE costs (14) .

Some studies that compared the sensitivity and specificity of SARS-CoV-2 diagnostic RT-qPCR tests between saliva and NPS samples have shown that sensitivity is higher using NPS (15) (16) (17) , while others show that saliva samples have a higher (14, 18, 19) or similar (20) (21) (22) sensitivity. Recent meta-analyses have shown that there is little difference in sensitivity between NPS and saliva samples for the detection of SARS-CoV-2 nucleic acid (23) (24) (25) . Although multiple studies have reported the presence of viral RNA . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint in saliva samples from both symptomatic and asymptomatic patients (21, 26, 27) , the timing of sample collection seems to be important, because the viral load of SARS-CoV-2 in saliva declines after disease onset (18, 28, 29) , highlighting the importance of collecting samples during the early phase of disease.

Thus, saliva sampling is not only easier, safer, and less expensive, but also a reliable option for COVID-19 testing.

Pooled testing, in which samples from multiple individuals are combined into a single test, havs been shown to be effective in multiple infectious disease screening settings, including for syphilis and HIV (30, 31) . During the current COVID-19 pandemic, a pooled-sample testing approach has been reported to save both cost and time when implemented on larger scales (30, 32, 33) . For pooled testing to be effective, certain baseline parameters should be considered: the prevalence or positivity rate within the community, sensitivity and specificity of the test, and the limits of detection. Multiple studies have published models and algorithms to calculate optimal pool sizes that depend on prevalence and cost reductions relative to individual tests (34) (35) (36) (37) (38) . Overall, sample pooling is most advantageous for populations with low prevalence, remaining more time-and cost-efficient than individual testing in populations with positivity rates up to around 30%; however, it offers no benefit when the positivity rate (prevalence) becomes higher (34) (35) (36) (37) (38) .

In our cohort of healthy and asymptomatic individuals who were scheduled for medical check-ups at the Center for Preventive Medicine at Keio University Hospital, only 3 of 2,342 (0.19%) individuals tested between August and December 2020 had positive results (39) , indicating low prevalence among asymptomatic individuals during this period. Taken together, pooled testing of saliva samples, especially for screening in communities with relatively low prevalence, should allow more efficient utilization of resources and more rapid screening of a greater number of people with faster turnaround times.

We proposed the concept of social PCR testing, which allows safe social and economic activities by routine testing of saliva samples from asymptomatic individuals (39) . Parallel implementation of mass screening coupled with sample pooling has been reported to contribute to the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint success of COVID-19 control (40) (41) (42) . Here, we report the results of SARS-CoV-2 PCR screening tests performed on 824 employees of Philips Japan, Ltd., who had neither symptoms nor close contact with infected individuals during the period of October through December 2020. Further, we analyzed the results of web questionnaires completed by 471 employees who had participated in the PCR screening regarding their attitudes toward mass-screening policies.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint

For initial evaluation, we used 25 saliva samples, determined as positive (4 samples) or negative (21 samples) by individual testing at Keio University Hospital. SARS-CoV-2 RNA in saliva was detected using a rapid RNA extraction-free RT-qPCR kit (SARS-CoV-2 Direct Detection RT-qPCR Kit; Takara Bio Inc., Shiga, Japan). This kit (approved by the Pharmaceuticals and Medical Devices Agency in Japan on October 27, 2020) (43) amplifies two regions of the nucleocapsid gene, N1 and N2, and a human internal control (IC) gene, as recommended by the US Centers for Disease Control and Prevention (44, 45) .

Two pooling approaches were assessed: collecting and pooling before virus inactivation, or inactivating before pooling. In the former approach, ten 8-µl saliva samples were pooled in a microtube 

Between October and December 2020, employees of Philips Japan, Ltd. were asked to participate in RT-qPCR screening. A total of 824 volunteers who provided informed consent were enrolled in this study. Eligible individuals included those who did not report fever above 37.5° C or . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint coughing, and had not been in close contact with COVID-19 patients during the two weeks preceding the test. Participants were instructed to collect 1-2 ml of saliva using a FastGene™ Saliva Collection Kit (Nippon Genetics Co., Ltd., Tokyo, Japan), at home, without restrictions on food timing or intake.

Samples were collected at each branch office, kept at 4°C, and sent to the LSI Medience Corporation Detection Kit -Multi-(TOYOBO Co., Ltd., Osaka, Japan) targeting the N1 and N2 genes, as well as an IC. This detection kit was developed for research use, but was approved for clinical use by the Japanese government in August 2020. RT-qPCR was performed using the COBAS z480 instrument (Roche Diagnostics K.K., Tokyo, Japan). The kit protocol was followed: 42°C for 5 min for RT;

pre-denaturation at 95°C for 10 s; and 45 cycles of 95°C for 5 s and 60°C for 30 s for amplification. Ct values were determined for N1, N2, and IC. Samples were considered positive for SARS-CoV-2 when either the N1 or N2 target was detected with a Ct < 40.

The 824 subjects who participated in the PCR screening were asked to respond anonymously to an online survey on how they felt about the social PCR screening in May, 2021. Participants received a clear explanation of the survey procedure and could interrupt or terminate the survey at any time without giving a reason.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint

For the questionnaire, sex differences in demographic characteristics and responses were assessed using Pearson's chi-squared test or Fisher's exact test, where appropriate. Statistical significance was set at p < 0.05. Data visualization and statistical analyses were performed using R v4.1.1.

This study was approved by the institutional review board of Keio University (approval number 20200291). The study was conducted according to the principles of the Declaration of Helsinki of 1964 and later versions. Written informed consent was obtained from all individuals who participated in the PCR screening tests, and informed consent was obtained from all individuals who participated in the survey, all prior to data collection.

We used known positive and negative samples to produce two pools, including positive samples P1 and P2, pooled before virus inactivation. Each pool contained a single known positive sample and nine samples that had tested negative. P1 had a Ct of 26.4 when tested alone, and 30.7 when pooled. P2 had a Ct of 34 when tested alone, and 37.1 when pooled (Supplementary Table 1 ).

Next, positive samples P3 and P4 were inactivated before being mixed with known negative samples. Table 1) .

Taken together, all six pilot pools, each combining one known positive with nine or 19 known negative samples) tested positive. As expected, increased Ct values were observed following dilution.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 ). In case 2, neither N1 nor N2 signals were detected in pooled testing, whereas individual testing identified both N1 and N2 (Ct 31.81 and 33.24, respectively) ( Figure 1B , Table 2 ). In both cases, individual testing showed sigmoid amplification curves for N1 and N2 at Ct values between 30 and 35. In case 2, the 10-sample pool exhibited no Ct value, but showed the start of a sigmoid amplification curve at the end of the cycle (red dotted box in Figure 1B ).

However, neither of the cases had Ct values or showed any late amplification of N2 in pools. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint 

Overall, for 1060 samples, 110 pooled-and 1060 individual tests were performed (Table 3) .

Only one pool was scored as probably positive; individual tests confirmed one positive case from this pool. PCR amplification was sometimes inhibited, as indicated by increased Ct for the IC genes. In general, the IC Ct values in most samples were 20-30. We defined inhibition when an IC Ct was unmeasurable or above 40, or when we observed no sigmoid amplification pattern ( Figure 2 ). In total, 74 individual samples and one pooled sample were in this category (Table 3) . Interestingly, these 74 samples showed normal range IC Ct values in pooled testing. These results indicate that pooling may have mitigated the inhibition of amplification observed in individual tests.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint 

Case one had felt chills six days prior to sample collection and visited the local clinic with symptoms including nasal discharge, sore throat, and sputum. The person was diagnosed as having a common cold, not tested for SARS-CoV-2. The person still had cold-like symptoms without fever when submitting sample. On receiving the positive PCR test result, the person underwent another PCR test with a saliva sample at a clinic two days after our screening, which was negative. The person had mild cold-like symptoms for 9-10 days, but developed no fever and required no treatment.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint Case two had no symptom when submitting sample. However, the person started to cough the next evening when received the positive test result, and developed more serious symptoms in the next morning, including a high fever. The person tested positive at a local clinic two days after the initial test. The fever subsided within two days, but other symptoms such as fatigue, coughing, sore throat, diarrhea, and altered smell and taste continued for a week. These symptoms gradually resolved and no medical intervention was required.

Of the 824 individuals who participated in PCR screening test, 476 (57.8%) completed the online questionnaire. As five respondents indicated that they did not want their survey results to be used for research purposes, we analyzed the responses from the remaining 471. The respondents included 358 males and 113 females, the majority between the ages of 30 and 50 years ( Figure 3A ). The locations of the participants were distributed across Japan, with the top three sites in the Kanto area (Tokyo, Kanagawa, and Saitama) ( Figure 3B ). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint Although no state of emergency was declared by the government during the study period, 62.8% of the respondents did not travel in the two weeks before testing (Q1, Figure 4 ). Most (79.8%) reported that they felt relieved by seeing the result (Q2). The 132 who responded "yes" to Q4 (Has your awareness been changed after participating in this screening project?) (N=132) were subsequently asked to provide more details, and 131 individuals gave analyzable comments: 81 commented on their awareness of infection prevention, stating that they became more careful or felt assured by their preventative measures (washing hands, avoiding crowds, limiting unnecessary outings, etc.); 42 commented on PCR testing: 23 noted that they realized that saliva PCR testing was easy and helpful; and 19 stated that the PCR testing should be performed regularly. The remaining eight commented that the relief of a negative test result is temporary and that PCR is not 100% accurate ( Figure 4 ). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint Individuals who answered "yes" to Q5 (Have you, your family member, or someone close contracted COVID-19 after the screening program?) (N=27) subsequently gave more specifics on who had contracted COVID-19: one reported his/her own infection, four reported that family members or living partners had become infected, and four reported that relatives who did not live with them later tested positive, six reported friends, and twelve reported colleagues or acquaintances at their workplace ( Figure 4) . Those who responded "yes" to Q6 (Do you think that routine PCR screening should be put into practice at the workplace?) were subsequently asked how much they would be willing to pay for such testing. It is notable that while the overwhelming majority of respondents agreed that routine PCR screening should be put into practice at the workplace, many were unwilling to pay out-of-pocket costs; 166 (38.6%) answered that they would not be tested unless the workplace tests were free, and 218 (48%) answered that they would pay if the cost was less than 1,999 JPN (approximately US$20) ( Figure   4 ). Demographic characteristics of the responders, questionnaire responses, and statistical tests for gender differences are summarized in Supplementary Table 2. Statistically significant difference between sexes were seen only for location (Fisher's exact test, p = 0.0005), Q3 (if participants underwent other PCR tests after this program, Chi-squared test p = 0.0078), and Q4-1 (specificity of awareness change, Fisher's exact test p = 0.036).

Although SARS-CoV-2 vaccines reduce the risk of symptomatic and severe disease and infection (46, 47) , breakthrough infections occur (3) (4) (5) and vaccine effectiveness against transmission is decreased for the delta variants (48, 49) . Additionally, vaccine protective effects decline considerably after six months, especially in older people, according to studies in the UK (50) and Israel (51). The recent surge of infections with delta and omicron variants across the world demonstrates that vaccines alone cannot fully contain viral spread, and that efficacy decreases over time and with immune escape . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint acquired by viral mutations (52) (53) (54) (55) . It is important to keep in mind that vaccines alone cannot end the pandemic; therefore, we need to orchestrate all available tools to win the fight against this global scourge, including rapid testing and screening, physical distancing, and sanitary precautions (56) .

Pooled testing has been shown to be a reliable option for rapid, large-scale, and cost-effective screening.

In this study, we compared the RT-qPCR results of pooled and individual saliva samples from Table 3 ), the mean positivity [(daily cases/tests) × 100] during the period was 13.3%, much higher than that in our cohort. This is probably because of the difference in the target populations; in the first case, PCR tests were performed for suspected individuals with symptoms or recent exposure or contact with confirmed COVID-19 patients. In the second, we see regional and time frame heterogeneity in positive rates, but rates ranged from 0 to 1.34%, comparable to our results.

Because pooling samples will dilute the viral load of a positive sample and tend to produce higher Ct, detecting samples with lower viral loads has been a major challenge in pooling approaches.

In our study, Positive Case 2 was not detected in a 10-sample pool. The Ct values for N1 and N2 in the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint individual test for this case were 31.81 and 33.24, respectively. In our preliminary pooled-sample testing, 10-sample pools resulted in Ct increases ranging from 2.5 to 4.3 (median, 3.25). If we simply add these values, Case 2 could have been detected in the 10-sample pool testing as well, with estimated Ct of 34.3~36.1 for N1 and 35.74~37.54 for N2, respectively. However, different RT-qPCR kits were used for the pilot tests (Takara) and the screening (Toyobo), so we cannot directly compare their results.

Consistent with our findings, previous studies showed similar Ct increases in pooled testing relative to individual testing, with variations in added values in pooled testing (15, 34, 57, 58) . Interestingly, some groups observed no Ct differences between pooled and individual RT-qPCR testing (59, 60). More et al. We also encountered a relatively high frequency of PCR inhibition in individual tests, defined as Ct values of IC being unmeasurable or above 40, or by no sigmoid PCR amplification pattern. Saliva can contain inhibitors that impair nucleic acid amplification (65, 66) . In addition to its molecular composition hindering RNA detection, saliva can be a challenging clinical sample because it varies across individuals in pH and viscosity, as well as being more susceptible to the effects of RNases (65) .

Several protocols have been proposed to overcome these challenges, such as dilution, chemical pretreatment, heating, and treatment with proteinase K (66). In our study, pooled sample testing exhibited less amplification inhibition than individual testing, suggesting that pooling may reduce saliva's inhibitory effects on PCR.

As case 1 had cold-like symptoms six days prior to sample collection, strictly speaking, the person was not asymptomatic. When the person underwent another RT-qPCR test at the local clinic, it was eight days after the onset of symptoms, at a relatively late phase of infection. We speculate that this is the reason the test was negative. Case 2 had no symptoms when the person submitted samples, and was pre-symptomatic (in an incubation period) when the person participated in the PCR screening. The RT-qPCR test detected infection before the person started to manifest symptoms. This finding reinforces the usefulness and clinical applicability of PCR testing.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint In our study, several participants submitted samples more than once during the study period.

There has been increasing evidence that success in containing SARS-CoV-2 depends more on the frequency and turnaround time of the testing than on the test being highly sensitive (67, 68).

Multiple factors can account for a high Ct (i.e., a weakly positive case): in very early phases of infection, where viral loads will likely increase, or during recovery, when fragmented viral RNA may be detected but may not be infective. In pooled testing, we may sometimes have negative false results because of decreased sensitivity, especially for samples with low viral loads. To increase the likelihood possibility of detecting vs. missing early infections in cases with high Ct values, repeated, regular testing is recommended in a mass-screening setting (67).

We also collected questionnaire responses from our participants. It is noteworthy that most of the respondents stated that PCR screening should be performed regularly to ensure a safer work environment. At the same time, the majority were willing to be tested only if screening was free or low cost. The current questionnaire results may be informative to companies, schools, governmental organizations, hospitals, and local communities that are considering screening programs.

In conclusion, pooled RT-qPCR testing of saliva samples is effective and efficient in screening populations with relatively low prevalence. Monitoring a late amplification pattern helps increase detecting positive cases in pooled testing. Regular and frequent screening testing is generally accepted; however, financial costs could be a barrier.

The authors thank Ms. Kaori Mochida for her technical assistance; Philips Japan, Ltd. for participating in the PCR screening study, conducting the survey, and collecting and sharing the data; Editage (www.editage.com) for English language editing; Dr. Akihito Hagihara for his advice on statistical analysis and interpretation; Dr. Scott E. Woodman (Houston, TX, USA) for proofreading our manuscript, and Dr. A. Gordon Robertson (Courtenay, BC, Canada) for his advice on data visualization, data analysis, and on the manuscript. This research was conducted as part of the Keio Donner Project . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

COVID-19 coronavirus pandemic

Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Assessing Asymptomatic, Presymptomatic, and Symptomatic Transmission Risk of Severe Acute Respiratory Syndrome Coronavirus 2

Asymptomatic carriage and transmission of SARS-CoV-2: What do we know?

Temporal dynamics in viral shedding and transmissibility of COVID-19

Genomic epidemiology of novel coronavirus

Interpreting Diagnostic Tests for SARS-CoV-2

Complications of COVID-19 Nasopharyngeal Swab Test

A Nasal Complication of Nasopharyngeal Swab for Reverse Transcription Polymerase Chain Reaction (RT-PCR) Detection of SARS-CoV-2 mRNA

Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic?

Saliva is a reliable tool to detect SARS-CoV-2

Pooled Saliva Specimens for SARS-CoV-2 Testing

CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2

Diagnostic accuracy and acceptability of molecular diagnosis of COVID-19 on saliva samples relative to nasopharyngeal swabs in tropical hospital and extra-hospital contexts: The COVISAL study

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19

Saliva is a reliable and accessible source for the detection of SARS-CoV-2

Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg

Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test

Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis

Comparing saliva and nasopharyngeal swab specimens in the detection of COVID-19: A systematic review and meta-analysis

The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis

Saliva samples for detection of SARS-CoV-2 in mildly symptomatic and asymptomatic patients

Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19

Consistent Detection of 2019 Novel Coronavirus in Saliva

Pooled Testing Strategies for SARS-CoV-2 diagnosis: A comprehensive review

Pooling of sera for human immunodeficiency virus (HIV) testing: an economical method for use in developing countries

19; Interim Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic and Screening Testing

Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples

Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources

A robust pooled testing approach to expand COVID-19 screening capacity

Optimally pooled viral testing

Optimization of group size in pool testing strategy for SARS-CoV-2: A simple mathematical model

RT-PCR Screening Tests for SARS-CoV-2 with Saliva Samples in Asymptomatic People: Strategy to Maintain Social and Economic Activities while Reducing the Risk of Spreading the Virus

Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg

Implementation of a Pooled Surveillance Testing Program for Asymptomatic SARS-CoV-2 Infections on a College Campus -Duke University

Research use only 2019-novel coronavirus (2019-nCcoVv) real-time RT-PCR primers and probes

Development of a New Multiplex Real-Time RT-PCR Assay for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway

Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK

Why scientists worldwide are watching UK COVID infections

CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

doi: medRxiv preprint 53. Taylor L. Covid-19: Omicron drives weekly record high in global infections

Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings

Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools

Sample pooling is a viable strategy for SARS-CoV-2 detection in low-prevalence settings

Comparing two sample pooling strategies for SARS-CoV-2 RNA detection for efficient screening of COVID-19

The Application of Sample Pooling for Mass Screening of SARS-CoV-2 in an Outbreak of COVID-19 in Vietnam

Pooling of Nasopharyngeal Swab Samples To Overcome a Global Shortage of Real-Time Reverse Transcription-PCR COVID-19 Test Kits

Pooled testing for COVID-19 diagnosis by real-time RT-PCR: A multi-site comparative evaluation of 5-& 10-sample pooling

Assessment of Sample Pooling for Clinical SARS-CoV-2 Testing

Intricacies in characterizing positivity in pooled sample testing for SARS-CoV-2

Inhibitory effect of salivary fluids on PCR: potency and removal

Rapid and Extraction-Free Detection of SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated Isothermal Amplification

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Acad Sci U S A. 2021;118 (21) . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22269880 doi: medRxiv preprint